At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit
Could Signal First Tremelimumab Approval
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.
You may also be interested in...
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.